Skip to main content
. 2016 Oct 28;63(12):1655–1660. doi: 10.1093/cid/ciw655

Figure 4.

Figure 4.

Effect of trimethoprim-sulfamethoxazole (TMP-SMX) treatment on neurocognitive performance. Latent Toxoplasma infection–positive participants who reported TMP-SMX use (n = 3) performed substantially better than nonusers (n = 17), but the power of this comparison was low due to small numbers of participants. Heights of bars are means; lines are standard errors.